#AHA20 – Randomized trial: In elective percutaneous coronary intervention Clopidogrel led to similar outcomes compared with Ticagrelor with less minor bleeding
16 Nov, 2020 | 01:55h | UTCNews release: Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty – American Heart Association
Commentaries: Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS – TCTMD AND Ticagrelor Not Superior to Clopidogrel for Elective PCI – NEJM Journal Watch
Commentary on Twitter
NEW Research—Clopidogrel vs ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial https://t.co/joepKHbgtu pic.twitter.com/gEyPl2HE80
— The Lancet (@TheLancet) April 30, 2020